Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Avid Bioservices Inc (CDMO)

Avid Bioservices Inc (CDMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 421,692
  • Shares Outstanding, K 56,603
  • Annual Sales, $ 59,700 K
  • Annual Income, $ -10,470 K
  • 60-Month Beta 2.27
  • Price/Sales 7.52
  • Price/Cash Flow N/A
  • Price/Book 9.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.03
  • Growth Rate Est. (year over year) +3,330,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.61 +10.98%
on 09/08/20
9.10 -19.41%
on 09/02/20
-1.01 (-12.11%)
since 08/21/20
3-Month
5.48 +33.76%
on 06/23/20
9.10 -19.41%
on 09/02/20
+1.71 (+30.43%)
since 06/22/20
52-Week
3.02 +142.72%
on 03/23/20
9.10 -19.41%
on 09/02/20
+1.37 (+22.99%)
since 09/20/19

Most Recent Stories

More News
Avid Bioservices Announces Move to Virtual-Only Annual Meeting of Stockholders on October 20, 2020

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that it will hold its 2020 Annual Meeting of Stockholders (the "Annual Meeting") solely by means of remote communication (i.e., a virtual-only...

CDMO : 7.30 (-2.01%)
CDMOP : 27.00 (-2.07%)
Avid Bioservices to Participate in 18th Annual Morgan Stanley Global Healthcare Conference

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development...

MS : 47.22 (-2.36%)
CDMO : 7.30 (-2.01%)
CDMOP : 27.00 (-2.07%)
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developments

-- Recorded First Quarter Revenue of $25.4 Million --

CDMO : 7.30 (-2.01%)
CDMOP : 27.00 (-2.07%)
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development...

CDMO : 7.30 (-2.01%)
CDMOP : 27.00 (-2.07%)
Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development...

CDMO : 7.30 (-2.01%)
CDMOP : 27.00 (-2.07%)
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2021 After Market Close on September 1, 2020

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services...

CDMO : 7.30 (-2.01%)
CDMOP : 27.00 (-2.07%)
Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine

Oragenics, Inc. (NYSE American: OGEN) and Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that the companies have entered into a process development and drug substance manufacturing...

OGEN : 0.6927 (-1.04%)
CDMO : 7.30 (-2.01%)
CDMOP : 27.00 (-2.07%)
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development...

CDMO : 7.30 (-2.01%)
CDMOP : 27.00 (-2.07%)
IOVA : 32.60 (-4.09%)
Happy Canada Day

Monday U.S. Economic Lookahead Pending Home Sales (May) Featured Earnings Micron Technology Inc. (NASDAQ:MU) ...

MU : 48.95 (-0.41%)
ATD-B.TO : 45.29 (+0.96%)
AYI : 99.48 (+0.39%)
CDMO : 7.30 (-2.01%)
CAG : 35.52 (+1.37%)
FDX : 238.14 (-0.25%)
MEI : 24.47 (-1.73%)
HBP.TO : 0.3900 (-4.88%)
STZ : 187.28 (+1.20%)
GIS : 58.45 (+1.00%)
UNF : 181.43 (+0.42%)
LNN : 92.92 (+0.08%)
RCH.TO : 34.20 (-0.44%)
MDF.TO : 7.01 (+1.01%)
ET.TO : 11.89 (-0.08%)
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services...

CDMO : 7.30 (-2.01%)
CDMOP : 27.00 (-2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CDMO with:

Business Summary

Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing...

See More

Key Turning Points

2nd Resistance Point 7.90
1st Resistance Point 7.67
Last Price 7.35
1st Support Level 7.22
2nd Support Level 7.00

See More

52-Week High 9.10
Last Price 7.35
Fibonacci 61.8% 6.77
Fibonacci 50% 6.06
Fibonacci 38.2% 5.34
52-Week Low 3.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar